Learn ($)

With the U.S. Tech Stock Bubble bursting in 2022, KeyStone continued to expand our watchlist of great SaaS stocks which continue to fall in price, but could be great long-term investments. The goals of this report are to gain insight into the general valuations of the segment, grow our book of knowledge on many of these high-quality technology-based businesses, identify a list of top-tier SaaS stocks we may look to deploy capital in over the course of 2022-2023, and potentially identify a couple of current buys following the significant 2022 year-to-date correction. Our screeners identified a group of roughly 400 U.S. tech-based stocks which our analysts ran through individually. Within the context of the larger tech segment, we focus on SaaS and traditional software businesses given their high margins, strong growth, and often sticky customer bases. Within this report, we have included statistical analysis on 49 SaaS focussed US stocks, including 16 individual reports and 3 buy recommendations. 

Recently, KeyStone analysts attended the 34th Annual ROTH Conference in California which included just under 500 publicly traded companies. Prior to the event, our analysts reviewed each attending company and screened the group with our growth-at-a-reasonable-price (GARP) model. Approximately 24 met a threshold of our model and we scheduled in person interviews with management teams from each company. Within this report we have provided statistical analysis on each company as well as summary Monitor reports on a number of companies we are monitoring from the event and Company Update reports on companies that we interviewed and are currently in coverage. While the research did not produce any new recommendations, we uncovered a number of interesting businesses that may enter our BUY coverage over the course of the next 12-months.

KeyStone’s 2022 Canadian Dividend All-Star Report is a comprehensive analysis of the complete universe of dividend stocks in the Canadian market. We identified approximately 400 dividend-paying stocks listed in Canada and applied KeyStone’s rigorous criteria to find the companies that provide the best value to investors. This report contains our current Focus BUY portfolio (comprised of what we consider to be the top 18 income stocks on the Canadian market) and data on an additional 62 stocks from our Monitor List.

This special US Research report individually reviewed approximately 3,500 NASDAQ (primarily) listed stocks with market caps under US$2 billion. The impetus of the project was to get a better understanding of current valuations, increase our analyst’s general knowledge of this set of companies and create a group of over 100 companies which have a threshold level of the GARP or growth at a reasonable price criterion we use to identify near and long-term investment opportunities.

The research produced a list of just over 130 stocks which we have provided statistical analysis on in the tables section. From these initial numbers and our initial review of the businesses, we produced a list of 38 stocks which we provide mini reports on detailing the businesses, current valuations, and merits as potential recommendations.

KeyStone has reviewed the public North American Cannabis market since inception. At legalization in Canada, we rejected all candidates as uninvestable due to a lack of profitability, high valuations and a significant production capacity overbuild. Over the ensuing year, Cannabis stocks across the board plummeted. In late 2019, a very select number of U.S. operating Cannabis stocks had emerged into profitability and one name finally met our criteria. The stock was recommended at $15.99 and reiterated less than a month later at $13.35 as a SPEC BUY. We have since added two smaller Cannabis operators in the U.S. market.  We continued to monitor players with operations primarily in the Canadian market but broadly speaking the operational struggles continued. Within this report we conduct statistical analysis on 31 Canadian Cannabis Operators, break down 8-10 of the businesses in more detail and make 3 recommendations in the U.S. Cannabis space.